Related Experiment Video
Updated: May 5, 2026
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Effect of calcium antagonists on sympathetic activity
1Hypertension Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Insights
Short-acting calcium antagonists acutely increase sympathetic activity, while long-acting non-dihydropyridine agents decrease it. This impacts understanding of cardiovascular outcomes in hypertension treatment.
Area of Science:
- Cardiovascular Pharmacology
- Hypertension Research
- Autonomic Nervous System
Background:
- Hypertension management often involves calcium antagonists.
- The impact of calcium antagonists on sympathetic nervous system activity requires clarification.
- Sympathetic overactivity is a key factor in cardiovascular disease.
Purpose of the Study:
- To evaluate the effects of calcium antagonists on sympathetic activity in hypertensive patients.
- To analyze how different classes and durations of action influence sympathetic markers.
- To correlate changes in sympathetic markers with hemodynamic parameters.
Main Methods:
- Systematic literature search of Medline (1975-May 1996).
- Inclusion of clinical studies on calcium antagonists, blood pressure, heart rate, and plasma norepinephrine (NE).
- Analysis based on calcium antagonist class (dihydropyridine vs. non-dihydropyridine) and duration of action (short-acting vs. long-acting).
Main Results:
- Short-acting (SA) calcium antagonists acutely increased heart rate and norepinephrine (NE) levels.
- Sustained therapy with SA calcium antagonists also elevated NE levels.
- Long-acting (LA) non-dihydropyridine agents showed a decrease in heart rate and NE levels, unlike LA dihydropyridines.
Conclusions:
- SA calcium antagonists stimulate sympathetic activity both acutely and long-term.
- LA non-dihydropyridine calcium antagonists appear to reduce sympathetic activation.
- Findings may explain increased morbidity and mortality observed with some SA calcium antagonists.
Objective:
We evaluated the effects of calcium antagonists on sympathetic activity in hypertensive patients by searching Medline for English language articles published between 1975 and May 1996 using the terms calcium antagonists, sympathetic nervous system and catecholamines.
Methods:
Data from clinical studies reporting only the effects of calcium antagonists on blood pressure, heart rate and plasma norepinephrine (NE) levels in patients with hypertension were analysed according to class of calcium antagonist (dihydropyridine vs non-dihydropyridine), their duration of action (short-acting (SA) vs long-acting (LA)) and treatment duration.
Results:
We identified 63 studies involving 1252 patients. Acutely after single dosing, SA calcium antagonists decreased mean arterial pressure by 13.7 +/- 1.1% and increased heart rate by 13.7 +/- 1.4% and NE levels by 28.6% +/- 2.5%. Change in NE levels correlated with change in heart rate (r = 0.59, P < 0.01) and inversely with change in arterial pressure (r = 0.46, P < 0.05) in patients taking dihydropyridine calcium antagonists acutely. With sustained therapy, both classes of SA calcium antagonists increased NE levels. Whereas NE levels remained slightly elevated and heart rate unchanged with LA dihydropyridine calcium antagonists, both heart rate and NE levels decreased with LA non-dihydropyridine calcium antagonists. SA calcium antagonists stimulate sympathetic activity when given acutely and over the long term, irrespective of their molecular structure. In contrast, sympathetic activation is less pronounced with LA dihydropyridine calcium antagonists and falls with LA non-dihydropyridine calcium antagonists.
Conclusions:
The present findings offer a possible pathophysiological explanation for the increase in morbidity and mortablity observed in some studies using SA calcium antagonists.
More Related Videos
06:30Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Related Concept Videos
01:28Drugs Acting on Autonomic Ganglia: Blockers
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...